Reimagining dementia screening: A stakeholder-informed perspective on artificial intelligence, digital biomarkers, and real-world implementation

Abstract

The approval of disease-modifying treatments for Alzheimer's disease demands a rethinking of cognitive screening. Drawing on over 180 stakeholder interviews from the NSF National I-Corps program, this perspective highlights barriers in current workflows, from time constraints in primary care to learning effects in long-term care, and presents innovation pathways centered on AI and digital biomarkers. Speech analysis, in particular, offers a scalable and cost-effective screening tool aligned with existing CPT codes. We outline implementation strategies and emphasize the urgent opportunity to align technological innovation with frontline clinical needs to ensure advances translate into meaningful patient and provider benefit.

Ähnliche Arbeiten